Abstract
Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / secondary
-
Aged
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Camptothecin / analogs & derivatives*
-
Camptothecin / therapeutic use*
-
Cardia
-
Esophageal Neoplasms / drug therapy*
-
Esophageal Neoplasms / pathology
-
Female
-
Humans
-
Irinotecan
-
Male
-
Middle Aged
-
Paclitaxel / therapeutic use*
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology
Substances
-
Antineoplastic Agents, Phytogenic
-
Irinotecan
-
Paclitaxel
-
Camptothecin